Prognostic Value of Metabolic Tumor Volume Estimated by F-18-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease

摘要

Purpose The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by F-18-fluorodeoxyglucose positron emission tomographycomputed tomography (FDG-PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximabcontaining immunochemotherapy. Methods Patients with newly diagnosed DLBCL who underwent pre-treatment torso FDG-PET/CT scan taken within 10 days before treatment were included. MTV was defined as the volume of hypermetabolic tissue with a standardized uptake value (SUV) greater than a threshold value of 2.5 and calculated using volume viewer software. Association of MTV with patient characteristics and survival were compared. Results A total of 96 patients were evaluated. During a median follow-up period of 27.8months, 3-year event-free survival (EFS) and overall survival was 69.5 and 72.9 , respectively. The Ann Arbor staging showed a limitation of prognosis because there was no difference of EFS between patients with Ann Arbor stage II and those with stage III. On the contrary, among patients with Ann Arbor stage II or III disease (n= 53), the higher MTV group showed significantly inferior EFS compared with the lower MTV group. Conclusions In the current study, we identified the pretreatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.